

DAFTAR PUSTAKA

1. WHO. *Tuberculosis*. 2021. <https://www.who.int>
2. Noviyani A, Nopsopon T, Pongpirul K. Variation of tuberculosis prevalence across diagnostic approaches and geographical areas of Indonesia. *PLoS One*. 2021 Oct;16(10):e0258809.
3. Suryawan. S DA, Siagian TH. Sex and Age Group Differences in The Spread of Tuberculosis In Indonesia: An Agent Based Modeling Approach. *Jurnal Aplikasi Statistika & Komputasi Statistik*; Vol 13 No 2 (2021): Journal of Statistical Application and Computational Statistics. 2021;
4. Puspita T, Suryatma A, Simarmata O, Veridona G, Lestary H, Athena A, et al. Spatial variation of tuberculosis risk in Indonesia 2010-2019. *Health Science Journal of Indonesia*. 2021 Dec;12(2 SE-Articles).
5. Tsani RM, Kasno. Gambaran Klinis Tuberkulosis Paru di RSUP Dr. Kariadi Semarang Periode Januari – Juni 2011. *Fakultas Kedokteran Universitas Muhammadiyah Semarang*. 2012;(2):33–9.
6. Tsani RM. Gambaran Klinis Tuberkulosis Paru di RSUP Dr. Kariadi Semarang Periode Januari – Juni 2011. *Gambaran Klinis Tuberkulosis Paru di RSUP Dr Kariadi Semarang Periode Januari – Juni 2011 Clinical Features of Pulmonary Tuberculosis at RSUP Dr Kariadi Semarang Period on January – June 2011*. 2012;(2):33–9.
7. Majdawati A, Inayati I. Optimalisasi Germas Melalui Kader ‘Aisyiyah Dalam Program Eliminasi Tuberculosis Pasca Terapi Tb. *Prosiding Seminar Nasional Program Pengabdian Masyarakat*. 2021;5(1):9–19.
8. Balaram Naik, P Karunakar,1 M Jayadev 1 and V Rahul Marshal2. No 主観的健康感を中心とした在宅高齢者における 健康関連指標に関する共分散構造分析Title. *J Conserv Dent* 2013. 2013;16(4):2013.
9. Christine T, Tarigan AP, Ananda FR. The Correlation between Levels of Transforming Growth Factor- β with Pulmonary Fibrosis in Post Pulmonary Tuberculosis in Medan, North Sumatera - Indonesia. *Open Access Maced J Med Sci*. 2019 Jul;7(13):2075–8.
10. Christine T, Tarigan AP, Ananda FR. The Correlation between Levels of Transforming Growth Factor- β with Pulmonary Fibrosis in Post Pulmonary Tuberculosis in Medan, North Sumatera - Indonesia. *Open Access Maced J Med Sci*. 2019 Jul;7(13):2075–8.
11. Hermendy BE, Dwi RP. Peran Transforming Growth Factor BETA (TGF- β) Pada Rinitis Alergi. *Jurnal THT-KL*. 2017;10(1):27–36.
12. Walton KL, Johnson KE, Harrison CA. Targeting TGF- β mediated SMAD signaling for the prevention of fibrosis. *Front Pharmacol*. 2017;8:461.
13. Organization WH. The republic of Indonesia joint external monitoring mission tuberculosis 2017 Final Report. Jakarta: WHO. 2017;
14. Singer-Leshinsky S. Pulmonary tuberculosis: Improving diagnosis and management. *Journal of the American Academy of PAs*. 2016;29(2):20–5.
15. Organization WH. The republic of Indonesia joint external monitoring mission tuberculosis 2017 Final Report. Jakarta: WHO. 2017;

16. Moule MG, Cirillo JD. Mycobacterium tuberculosis dissemination plays a critical role in pathogenesis. *Front Cell Infect Microbiol.* 2020;10:65.
17. Chai Q, Zhang Y, Liu CH. Mycobacterium tuberculosis: an adaptable pathogen associated with multiple human diseases. *Front Cell Infect Microbiol.* 2018;8:158.
18. Chai Q, Zhang Y, Liu CH. Mycobacterium tuberculosis: an adaptable pathogen associated with multiple human diseases. *Front Cell Infect Microbiol.* 2018;8:158.
19. Evans S, Butler JR, Mattila JT, Kirschner DE. Systems biology predicts that fibrosis in tuberculous granulomas may arise through macrophage-to-myofibroblast transformation. *PLoS Comput Biol.* 2020;16(12):e1008520.
20. Maharaj S, Shimbori C, Kolb M. Fibrocytes in pulmonary fibrosis: a brief synopsis. *European Respiratory Review.* 2013;22(130):552–7.
21. Evans S, Butler JR, Mattila JT, Kirschner DE. Systems biology predicts that fibrosis in tuberculous granulomas may arise through macrophage-to-myofibroblast transformation. *PLoS Comput Biol.* 2020;16(12):e1008520.
22. Christine T, Tarigan AP, Ananda FR. The Correlation between Levels of Transforming Growth Factor- β with Pulmonary Fibrosis in Post Pulmonary Tuberculosis in Medan, North Sumatera - Indonesia. *Open Access Maced J Med Sci.* 2019 Jul;7(13):2075–8.
23. Machida K, Maekura R. State of the art: sequelae of tuberculosis. *Kekkaku:[Tuberculosis].* 2005;80(10):655–74.
24. Sotgiu G, Centis R, Migliori GB. Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating. *Lancet Glob Health.* 2021;9(12):e1628–9.
25. Aggarwal N, Ghosh T, Bhan M, Dwarakanathan V, Sethi P, Meena VP, et al. Post-tuberculosis sequelae and their correlation with quality of life: An observational study at a tertiary care center of north India. *medRxiv.* 2021;
26. Aggarwal N, Ghosh T, Bhan M, Dwarakanathan V, Sethi P, Meena VP, et al. Post-tuberculosis sequelae and their correlation with quality of life: An observational study at a tertiary care center of north India. *medRxiv.* 2021;
27. Aggarwal N, Ghosh T, Bhan M, Dwarakanathan V, Sethi P, Meena VP, et al. Post-tuberculosis sequelae and their correlation with quality of life: An observational study at a tertiary care center of north India. *medRxiv.* 2021;
28. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. *European Respiratory Review.* 2018 Mar;27(147):170077.
29. Rhee CK, Yoo KH, Lee JH, Park MJ, Kim WJ, Park YB, et al. Clinical characteristics of patients with tuberculosis-destroyed lung. *The international journal of tuberculosis and lung disease.* 2013;17(1):67–75.
30. Serra R. Transforming Growth Factor beta (TGF β). *eLS.* 2002;(September 2002).
31. Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, et al. Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF- β signaling. *Free Radic Biol Med.* 2019;130:163–73.
32. Serra R. Transforming Growth Factor beta (TGF β). *eLS.* 2002;(September 2002).

33. Paré G, Çaku A, McQueen M, Anand SS, Enas E, Clarke R, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. *Circulation*. 2019;139(12):1472–82.
34. Zhong Z, Wu T, Zhu T, Pang Y, Li Q, Su P. Identification , molecular evolution , and expression analysis of the transcription factor Smad gene family in lamprey. *Mol Immunol*. 2021;136(January):128–37.
35. Yuek L, Lai S, Peter N, Gowripalan A, Michael L, Peter T. European Journal of Cell Biology SMAD proteins : Mediators of diverse outcomes during infection. *Eur J Cell Biol*. 2022;101(2):151204.
36. Yuek L, Lai S, Peter N, Gowripalan A, Michael L, Peter T. European Journal of Cell Biology SMAD proteins : Mediators of diverse outcomes during infection. *Eur J Cell Biol*. 2022;101(2):151204.
37. Gern BH, Adams KN, Plumlee CR, Stoltzfus CR, Shehata L, Moguche AO, et al. TGF β restricts expansion, survival, and function of T cells within the tuberculous granuloma. *Cell Host Microbe*. 2021;29(4):594-606.e6.
38. Gern BH, Adams KN, Plumlee CR, Stoltzfus CR, Shehata L, Moguche AO, et al. TGF β restricts expansion, survival, and function of T cells within the tuberculous granuloma. *Cell Host Microbe*. 2021;29(4):594-606.e6.
39. Domingo-Gonzalez R, Prince O, Cooper A, Khader SA. Cytokines and chemokines in Mycobacterium tuberculosis infection. *Tuberculosis and the Tubercle Bacillus: Second Edition*. 2017;33–72.
40. Manuscript A. NIH Public Access. 2013;75(3):301–4.
41. Difazio RM, Mattila JT, Klein EC, Cirrincione LR, Howard M, Wong EA, et al. Active transforming growth factor- β is associated with phenotypic changes in granulomas after drug treatment in pulmonary tuberculosis. *DARU, Journal of Pharmaceutical Sciences*. 2016;24(1):1–11.
42. Singh M, Vaughn C, Sasaninia K, Yeh C, Mehta D, Khieran I, et al. Understanding the relationship between glutathione, tgf- β , and vitamin d in combating mycobacterium tuberculosis infections. *J Clin Med*. 2020;9(9):1–15.
43. Boutanquoi PM, Burgy O, Burgy O, Beltramo G, Beltramo G, Beltramo G, et al. TRIM33 prevents pulmonary fibrosis by impairing TGF- β 1 signalling. *European Respiratory Journal*. 2020;55(6):1–13.
44. Kapoor M. Mechanisms of fibrosis. *Semin Cell Dev Biol*. 2020;101:77.
45. Global Tuberculosis Report 2023. World Health Organization; 2023.
46. El-Mouhdi K, El Omari H, Ouarrak K, El Amrani J, Zouine N, Lhilali I, et al. Pulmonary Tuberculosis in Hospital Setting: Retrospective Study on Risk Factors. *Tropical Journal of Natural Product Research*. 2023 Jul 31;7(7):3371–5.
47. Safwat TM, Abdel Fattah EB, Soliman AG. Gender differences in pulmonary tuberculosis in Abbassia Chest Hospital. *Egyptian Journal of Bronchology*. 2019 Sep;13(3):408–15.
48. Mlondo MN, Melesse SF, Mwambi HG. Risk Factors Associated with Tuberculosis Among Men; A Study of South Africa. *Open Public Health J*. 2022 Apr 27;15(1).
49. Chen J, Zha S, Hou J, Lu K, Qiu Y, Yang R, et al. Dose-response relationship between body mass index and tuberculosis in China: a population-based cohort study. *BMJ Open*. 2022;12(3):e050928.

50. Choi H, Yoo JE, Han K, Choi W, Rhee SY, Lee H, et al. Body Mass Index, Diabetes, and Risk of Tuberculosis: A Retrospective Cohort Study. *Front Nutr.* 2021;8(December):1–11.
51. Yoon HY, Kim H, Bae Y, Song JW. Body mass index is associated with clinical outcomes in idiopathic pulmonary fibrosis. *Sci Rep.* 2024 Dec 1;14(1).
52. Kim TH, Shin YY, Kim HJ, Song MJ, Kim YW, Lim SY, et al. Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone. *Sci Rep.* 2022 Dec 1;12(1).
53. Casha AR, Scarci M. The link between tuberculosis and body mass index. *J Thorac Dis.* 2017;9(3):E301–3.
54. Manji M, Shayo G, Mamuya S, Mpembeni R, Jusabani A, Mugusi F. Lung functions among patients with pulmonary tuberculosis in Dar es Salaam - A cross-sectional study. *BMC Pulm Med.* 2016;16(1):1–9.
55. He M, Yang X, Zhang Z, Liu Z. Impaired pulmonary function and associated factors in the elderly with tuberculosis on admission: a preliminary report. *BMC Infect Dis.* 2023 Dec 1;23(1).
56. Xing Z, Sun T, Janssens JP, Chai D, Liu W, Tong Y, et al. Airflow obstruction and small airway dysfunction following pulmonary tuberculosis: a cross-sectional survey. *Thorax.* 2023 Mar 1;78(3):274–80.
57. Manji M, Shayo G, Mamuya S, Mpembeni R, Jusabani A, Mugusi F. Lung functions among patients with pulmonary tuberculosis in Dar es Salaam - A cross-sectional study. *BMC Pulm Med.* 2016;16(1).
58. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al. Pulmonary impairment after tuberculosis. *Chest.* 2007;131(6):1817–24.
59. Ozoh OB, Ojo OO, Dania MG, Dede SK, Adegboyega OA, Irurhe NK, et al. Impact of post-tuberculosis lung disease on health-related quality of life in patients from two tertiary hospitals in lagos, Nigeria. *African Journal of Thoracic and Critical Care Medicine.* 2021;27(2):46–52.
60. Frangogiannis NG. Transforming growth factor- β in tissue fibrosis. Vol. 217, *Journal of Experimental Medicine.* Rockefeller University Press; 2020.
61. Du Y, Xiao H, Wan J, Wang X, Li T, Zheng S, et al. Atorvastatin attenuates TGF- β 1-induced fibrogenesis by inhibiting Smad3 and MAPK signaling in human ventricular fibroblasts. *Int J Mol Med.* 2020 Aug 1;46(2):633–40.
62. Yang JC, Xu C, Kang JQ, Yang L. Therapeutic ultrasound ameliorates pulmonary fibrosis through inhibiting TGF- β /SMAD-mediated epithelial mesenchymal transition [Internet]. 2022. Available from: <https://www.researchsquare.com/article/rs-1935194/v1>
63. Wu W, Wang X, Yu X, Lan HY. Smad3 Signatures in Renal Inflammation and Fibrosis. Vol. 18, *International Journal of Biological Sciences.* Ivyspring International Publisher; 2022. p. 2795–806.
64. Brake SJ, Lu W, Chia C, Haug G, Larby J, Hardikar A, et al. Transforming growth factor- β 1 and SMAD signalling pathway in the small airways of smokers and patients with COPD: potential role in driving fibrotic type-2 epithelial mesenchymal transition. *Front Immunol.* 2023;14.
65. Yuek L, Lai S, Peter N, Gowripalan A, Michael L, Peter T. European Journal of Cell Biology SMAD proteins : Mediators of diverse outcomes during infection. *Eur*

- J Cell Biol [Internet]. 2022;101(2):151204. Available from: <https://doi.org/10.1016/j.ejcb.2022.151204>
66. Chen C, Li X, Zhou T, Su Y, Yu B, Jin J, et al. Ubiquitin like protein FAT10 repressed cardiac fibrosis after myocardial ischemic via mediating degradation of Smad3 dependent on FAT10-proteasome system. *Int J Biol Sci*. 2023;19(3):881–96.
 67. Ding L, Li Y, Yang Y, Song S, Qi H, Wang J, et al. Wenfei Buqi Tongluo Formula Against Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF- β /Smad3 Pathway. *Front Pharmacol*. 2022 Jan 21;12.
 68. Wu Y, Li Y, Bai Y, Jiang J, Wang X, Chen Y, et al. Clinical significance of serum transforming growth factor- β 1 and procollagen type I N-propeptide in post-tuberculosis tracheobronchial stenosis. *Exp Ther Med*. 2021 Mar 29;21(6).
 69. Dinicolantonio JJ, McCarty MF, Barroso-Aranda J, Assanga S, Lujan LML, O’Keefe JH. A nutraceutical strategy for downregulating TGF β signalling: Prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis. Vol. 8, *Open Heart*. BMJ Publishing Group; 2021.
 70. Difazio RM, Mattila JT, Klein EC, Cirrincione LR, Howard M, Wong EA, et al. Active transforming growth factor- β is associated with phenotypic changes in granulomas after drug treatment in pulmonary tuberculosis. *DARU, Journal of Pharmaceutical Sciences*. 2016;24(1):1–11.
 71. Christine T, Tarigan AP, Ananda FR. The correlation between levels of transforming growth factor- β with pulmonary fibrosis in post pulmonary tuberculosis in Medan, North Sumatera - Indonesia. *Open Access Maced J Med Sci*. 2019;7(13):2075–8.
 72. Shi X, Young CD, Zhou H, Wang X. Transforming growth factor- β signaling in fibrotic diseases and cancer-associated fibroblasts. Vol. 10, *Biomolecules*. MDPI AG; 2020. p. 1–22.
 73. Inui N, Sakai S, Kitagawa M. Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to tgf- β and the ubiquitin-proteasome pathway. Vol. 22, *International Journal of Molecular Sciences*. MDPI; 2021.
 74. Kim HS, Meang MK, Kim S, Lee JY, Seong BL, Kim IH, et al. A noble TGF β biogenesis inhibitor exhibits both potent anti-fibrotic and anti-inflammatory capabilities [Internet]. 2019. Available from: <http://biorxiv.org/lookup/doi/10.1101/770404>
 75. Calthorpe RJ, Poulter C, Smyth AR, Sharkey D, Bhatt J, Jenkins G, et al. Complex roles of TGF-b signaling pathways in lung development and bronchopulmonary dysplasia. Vol. 324, *American Journal of Physiology - Lung Cellular and Molecular Physiology*. American Physiological Society; 2023. p. L285–96.
 76. Difazio RM, Mattila JT, Klein EC, Cirrincione LR, Howard M, Wong EA, et al. Active transforming growth factor- β is associated with phenotypic changes in granulomas after drug treatment in pulmonary tuberculosis. *DARU, Journal of Pharmaceutical Sciences* [Internet]. 2016;24(1):1–11. Available from: <http://dx.doi.org/10.1186/s13069-016-0043-3>
 77. Wang X, Wang J, Huang G, Li Y, Guo S. miR-320a-3P alleviates the epithelial-mesenchymal transition of A549 cells by activation of STAT3/SMAD3 signaling in a pulmonary fibrosis model. *Mol Med Rep*. 2021 May 1;23(5).

78. Shanmugasundaram K, Talwar A, Madan K, Bade G. Pulmonary Functions and Inflammatory Biomarkers in Post-Pulmonary Tuberculosis Sequelae. *Tuberc Respir Dis (Seoul)*. 2022;85(2):175–84.
79. Saito A, Horie M, Nagase T. TGF- β signaling in lung health and disease. *Int J Mol Sci*. 2018;19(8):1–18.
80. Wilson TM, Bolt M, Stahly A, Lee JS, Bang TJ, Sachs PB, et al. Transforming growth factor-beta is increased in sputum from individuals with rheumatoid arthritis-associated pulmonary fibrosis. *Rheumatology*. 2025 Jun 1;64(6):3989–95.
81. Sun Q, Fang L, Tang X, Lu S, Tamm M, Stolz D, et al. TGF- β Upregulated Mitochondria Mass through the SMAD2/3 $\rightarrow$ C/EBP β $\rightarrow$ PRMT1 Signal Pathway in Primary Human Lung Fibroblasts. *The Journal of Immunology*. 2019 Jan 1;202(1):37–47.
82. Bonecini-Almeida MG, Ho JL, Bo  chat N, Huard RC, Chitale S, Doo H, et al. Down-Modulation of Lung Immune Responses by Interleukin-10 and Transforming Growth Factor β (TGF- β) and Analysis of TGF- β Receptors I and II in Active Tuberculosis. *Infect Immun*. 2004 May;72(5):2628–34.
83. Yao F, Xu M, Dong L, Shen X, Shen Y, Jiang Y, et al. Sinomenine attenuates pulmonary fibrosis by downregulating TGF- β 1/Smad3, PI3K/Akt and NF- κ B signaling pathways. *BMC Pulm Med*. 2024 Dec 1;24(1).
84. Gao S, Li X, Jiang Q, Liang Q, Zhang F, Li S, et al. PKM2 promotes pulmonary fibrosis by stabilizing TGF- β 1 receptor I and enhancing TGF- β 1 signaling [Internet]. Vol. 8, *Sci. Adv*. 2022. Available from: <https://www.science.org>
85. Gupte AN, Selvaraju S, Gaikwad S, Mave V, Kumar P, Babu S, et al. Higher interleukin-6 levels and changes in transforming growth factor- β are associated with lung impairment in pulmonary tuberculosis. *ERJ Open Res*. 2021 Jan;7(1):00390–2020.
86. Gern BH, Adams KN, Plumlee CR, Stoltzfus CR, Shehata L, Busman-Sahay K, et al. TGF β restricts T cell function and bacterial control within the tuberculous granuloma [Internet]. 2019. Available from: <http://biorxiv.org/lookup/doi/10.1101/696534>
87. Wu M, Aung H, Hirsch CS, Toossi Z. Inhibition of Mycobacterium tuberculosis-Induced Signalling by Transforming Growth Factor- β in Human Mononuclear Phagocytes. *Basic Immunology*. 2011;
88. Windish HP, Lin PL, Mattila JT, Green AM, Onuoha EO, Kane LP, et al. Aberrant TGF- β signaling reduces T regulatory cells in ICAM-1-deficient mice, increasing the inflammatory response to Mycobacterium tuberculosis . *J Leukoc Biol*. 2009 May 19;86(3):713–25.
89. Ko JW, Shin NR, Park JW, Park SH, Lee IC, Kim JS, et al. Copper oxide nanoparticles induce collagen deposition via TGF- β 1/Smad3 signaling in human airway epithelial cells. *Nanotoxicology*. 2018 Mar 16;12(3):239–50.
90. Sun W, Kim DH, Byon CH, Choi HI, Park JS, Bae EH, et al. β -Elemene Attenuates Renal Fibrosis in the Unilateral Ureteral Obstruction Model by Inhibition of STAT3 and Smad3 Signaling via Suppressing MyD88 Expression. *Int J Mol Sci*. 2022 May 1;23(10).

91. Park HS, Back YW, Jang IT, Lee KI, Son YJ, Choi HG, et al. Mycobacterium tuberculosis Rv2145c Promotes Intracellular Survival by STAT3 and IL-10 Receptor Signaling. Front Immunol. 2021 May 4;12.

